Visa warned the telehealth company in July that it was being placed in a monitoring program for merchants, a move triggered by a flood of credit-card disputes from customers who said they were charged for subscriptions they did not want or could not cancel. The warning is aimed at one slice of the business, but it happens to be the slice that matters most.
The Visa penalty adds an $8 fee for each disputed transaction, which will hit nearly $75,000 in September alone. That is not a bank-breaking number for a company this size, but it is a loud signal that something is rubbing customers the wrong way.
Visa's dispute program is like a noise complaint from the credit card network. When too many customers call their bank and say "I did not authorize this charge," the payment processor takes notice. The threshold is simple: Hims needs to keep card disputes below 1.5% of all transactions for three straight months. Missing that mark could mean higher fees or losing the ability to process card payments altogether.
Part of the tension comes from how the memberships actually work. The first month costs $39, then jumps to $149 a month after that, and charges renew automatically. Some customers say they did not realize they signed up for recurring charges, and others say they kept getting billed even after trying to cancel.
Subscription disputes can hurt any business, so grab the free Always Be Buying E-Book to build wealth steadily
They say Hims made cancellation difficult and placed unwanted charges on customers. Hims has pushed back, arguing that the FTC ignored substantial evidence from a nearly three-year investigation.
A company spokesperson says Hims takes its responsibility to be transparent with its almost 3 million subscribers seriously. The company says it is working on clearer alerts about upcoming charges and notes that disputed charges are a small share of its business. But the social media and Better Business Bureau complaints tell a simpler story: some customers feel trapped in a loop they did not sign up for.
Hims is trying to move past the fad phase of weight loss drugs. The company has about 2.9 million subscribers and wants to be seen as a serious health care provider, not just to grab a trendy injection. It is shifting toward partnerships with established drugmakers like Novo Nordisk and moving away from compounded versions of popular weight loss drugs.
That strategy makes sense, but trust is the foundation of any subscription business, especially in health care. If customers feel tricked by the billing, they will not stay long enough to benefit from the partnerships.
For your portfolio, this is a reminder to look beyond the headline numbers when evaluating a stock like this. Fast growth is exciting, but the cost of acquiring a customer goes up when customers feel burned. The company has argued that the FTC's case is weak after a nearly three-year investigation, and a resolution may not come until August 2026. The question is whether Hims can clean up its cancellation process and quiet the complaints before that plays out in court.
Promotions might grow a subscriber base quickly for now. Keeping those subscribers happy is a different challenge entirely. And with Visa watching the chargeback rate, the next few months could tell us a lot about how solid that foundation really is.
When payment networks crack down, remember the Always Be Buying E-Book for a simpler path to wealth
